Synthesis and binding potencies of cyclohexapeptide somatostatin analogs containing naphthylalanine and arylalkyl peptoid residues

We report the synthesis, binding affinities to the recombinant human somatostatin receptors, and structure‐activity relationship studies of compounds related to the cyclic hexapeptide, c‐[Pro6‐Phe7‐D‐Trp8‐Lys9‐Thr10‐Phe11], L‐363,301 (the numbering in the sequence refers to the position of the resid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of peptide science 1999-03, Vol.5 (3), p.113-130
Hauptverfasser: Tran, Thuy-Anh, Mattern, Ralph-Heiko, Morgan, Barry A., Taylor, John E., Goodman, Murray
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 130
container_issue 3
container_start_page 113
container_title Journal of peptide science
container_volume 5
creator Tran, Thuy-Anh
Mattern, Ralph-Heiko
Morgan, Barry A.
Taylor, John E.
Goodman, Murray
description We report the synthesis, binding affinities to the recombinant human somatostatin receptors, and structure‐activity relationship studies of compounds related to the cyclic hexapeptide, c‐[Pro6‐Phe7‐D‐Trp8‐Lys9‐Thr10‐Phe11], L‐363,301 (the numbering in the sequence refers to the position of the residues in native somatostatin). The Pro residue in this compound is replaced with the arylalkyl peptoid residues Nphe (N‐benzylglycine), (S)βMeNphe [(S)‐N‐[(α‐methyl)benzyl]glycine] or (R)βMeNphe [(R)‐N‐[(α‐methyl)benzyl]glycine] and l‐1‐naphthylalanine is incorporated into either position 7 or 11 of the parent compound. The synthesis and binding data of the Nnal6 ([N‐naphthylmethyl]glycine) analog of L‐363,301 is also reported. The incorporation of the Nnal residue into position 6 of L‐363,301 resulted in an analog with weaker binding affinities to all hsst receptors but enhanced selectivity towards the hsst2 receptor compared with the parent compound. The other compounds bind effectively to the hsst2 receptor but show some variations in the binding to the hsst3 and hsst5 receptors resulting in different ratios of binding affinities to the hsst5 and hsst2 or hsst3 and hsst2, respectively. The incorporation of the Nphe residue into position 6 and the Nal residue into position 7 of L‐363,301 led to a compound which binds potently to the hsst2 and has increased selectivity towards this receptor (weaker binding to hsst3 and hsst5 receptors) compared with the parent compound. The analogs with β‐methyl chiral substitutions in the aromatic peptoid side chain and Nal in position 7 or 11 bind effectively to the hsst2 and hsst5 receptors. They exhibit similar ratios of binding affinities to the hsst5 and hsst2 receptors as observed for L‐363,301. There are however minor differences in binding to the hsst3 receptor among these analogs. These studies allow us to investigate the influence of additional hydrophobic groups on the binding activity to the isolated human somatostatin receptors and the results are important for the design of other somatostatin analogs. Copyright © 1999 European Peptide Society and John Wiley & Sons, Ltd.
doi_str_mv 10.1002/(SICI)1099-1387(199903)5:3<113::AID-PSC176>3.0.CO;2-N
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21151279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21151279</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3806-1a8466c57dd06b5442c82acdeb82d43123f922fe2fcc5214e59422b90c80bb7e3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQQCNEJUrhP-SE2kMWf8RxskClEmC7VbWLFFCPI8d2uqbZOMSuaK78cpym2guIkz1jzZvxvCj6gNECI0Tenlbrcn2GUVEkmOb8FBdFgegZW9L3GNPl8mL9KflalZhn53SBFuX2HUk2z6LjQ8Xz6c5ZQjLMX0QvnfuBUHhj2XH0uxo7v9POuFh0Kq5Np0x3G_fW604a7WLbxHKUrd3pB9Hr3hulY2f3wlvnhTddKBOtvXWxtJ0XppuqO9Hv_G5sRStCrB_JYpjiu7GNJ4o1Kh5CV3Wv3avoqBGt06-fzpPo-5fP38rL5Hq7WpcX14mkOcoSLPI0yyTjSqGsZmlKZE6EVLrOiUopJrQpCGk0aaRkBKeaFSkhdYFkjuqaa3oSvZm5_WB_hr4e9sZJ3YYhtb13QDBmmPCCHgaQg3Vu0A30g9mHDwBGMBkBmIzAtF-Y9guzEWBAIRgBCEZgNhIyCMotENgE7s3M_WVaPf4F_T_zn8inTCAnM9k4rx8OZDHcQcYpZ3CzWcHHVcWrqxRDRv8Azpqx1Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21151279</pqid></control><display><type>article</type><title>Synthesis and binding potencies of cyclohexapeptide somatostatin analogs containing naphthylalanine and arylalkyl peptoid residues</title><source>Wiley Journals</source><creator>Tran, Thuy-Anh ; Mattern, Ralph-Heiko ; Morgan, Barry A. ; Taylor, John E. ; Goodman, Murray</creator><creatorcontrib>Tran, Thuy-Anh ; Mattern, Ralph-Heiko ; Morgan, Barry A. ; Taylor, John E. ; Goodman, Murray</creatorcontrib><description>We report the synthesis, binding affinities to the recombinant human somatostatin receptors, and structure‐activity relationship studies of compounds related to the cyclic hexapeptide, c‐[Pro6‐Phe7‐D‐Trp8‐Lys9‐Thr10‐Phe11], L‐363,301 (the numbering in the sequence refers to the position of the residues in native somatostatin). The Pro residue in this compound is replaced with the arylalkyl peptoid residues Nphe (N‐benzylglycine), (S)βMeNphe [(S)‐N‐[(α‐methyl)benzyl]glycine] or (R)βMeNphe [(R)‐N‐[(α‐methyl)benzyl]glycine] and l‐1‐naphthylalanine is incorporated into either position 7 or 11 of the parent compound. The synthesis and binding data of the Nnal6 ([N‐naphthylmethyl]glycine) analog of L‐363,301 is also reported. The incorporation of the Nnal residue into position 6 of L‐363,301 resulted in an analog with weaker binding affinities to all hsst receptors but enhanced selectivity towards the hsst2 receptor compared with the parent compound. The other compounds bind effectively to the hsst2 receptor but show some variations in the binding to the hsst3 and hsst5 receptors resulting in different ratios of binding affinities to the hsst5 and hsst2 or hsst3 and hsst2, respectively. The incorporation of the Nphe residue into position 6 and the Nal residue into position 7 of L‐363,301 led to a compound which binds potently to the hsst2 and has increased selectivity towards this receptor (weaker binding to hsst3 and hsst5 receptors) compared with the parent compound. The analogs with β‐methyl chiral substitutions in the aromatic peptoid side chain and Nal in position 7 or 11 bind effectively to the hsst2 and hsst5 receptors. They exhibit similar ratios of binding affinities to the hsst5 and hsst2 receptors as observed for L‐363,301. There are however minor differences in binding to the hsst3 receptor among these analogs. These studies allow us to investigate the influence of additional hydrophobic groups on the binding activity to the isolated human somatostatin receptors and the results are important for the design of other somatostatin analogs. Copyright © 1999 European Peptide Society and John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 1075-2617</identifier><identifier>EISSN: 1099-1387</identifier><identifier>DOI: 10.1002/(SICI)1099-1387(199903)5:3&lt;113::AID-PSC176&gt;3.0.CO;2-N</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>(R)-N-(α-methyl)benzylglycine ; (R)βMeNphe ; (R)βMeNphe, (R)‐N‐(α‐methyl)benzylglycine ; (S)-N-(α-methyl)benzylglycine ; (S)βMeNphe ; (S)βMeNphe, (S)‐N‐(α‐methyl)benzylglycine ; 1-ethyl-3-(3′-dimethylaminopropyl)-carbodiimide ; 4-EM ; 4-ethylmorpholine ; 4‐EM, 4‐ethylmorpholine ; binding activities ; DCM ; DCM, dichloromethane ; dichloromethane ; DIEA ; DIEA, diisopropylethylamine ; diisopropylethylamine ; diphenylphosphoryl azide ; DPPA ; DPPA, diphenylphosphoryl azide ; EDC ; EDC, 1‐ethyl‐3‐(3′‐dimethylaminopropyl)‐carbodiimide ; GH, growth hormone ; growth hormone ; hsst receptor ; hsst receptor, recombinant human somatostatin receptor ; hsst receptors ; N-(naphthylmethyl)glycine ; N-benzylglycine ; Nnal ; Nnal, N‐(naphthylmethyl)glycine ; Nphe ; Nphe, N‐benzylglycine ; peptoids ; recombinant human somatostatin receptor ; somatostatin analogs ; synthesis</subject><ispartof>Journal of peptide science, 1999-03, Vol.5 (3), p.113-130</ispartof><rights>Copyright © 1999 European Peptide Society and John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3806-1a8466c57dd06b5442c82acdeb82d43123f922fe2fcc5214e59422b90c80bb7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291099-1387%28199903%295%3A3%3C113%3A%3AAID-PSC176%3E3.0.CO%3B2-N$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291099-1387%28199903%295%3A3%3C113%3A%3AAID-PSC176%3E3.0.CO%3B2-N$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Tran, Thuy-Anh</creatorcontrib><creatorcontrib>Mattern, Ralph-Heiko</creatorcontrib><creatorcontrib>Morgan, Barry A.</creatorcontrib><creatorcontrib>Taylor, John E.</creatorcontrib><creatorcontrib>Goodman, Murray</creatorcontrib><title>Synthesis and binding potencies of cyclohexapeptide somatostatin analogs containing naphthylalanine and arylalkyl peptoid residues</title><title>Journal of peptide science</title><addtitle>J. Peptide Sci</addtitle><description>We report the synthesis, binding affinities to the recombinant human somatostatin receptors, and structure‐activity relationship studies of compounds related to the cyclic hexapeptide, c‐[Pro6‐Phe7‐D‐Trp8‐Lys9‐Thr10‐Phe11], L‐363,301 (the numbering in the sequence refers to the position of the residues in native somatostatin). The Pro residue in this compound is replaced with the arylalkyl peptoid residues Nphe (N‐benzylglycine), (S)βMeNphe [(S)‐N‐[(α‐methyl)benzyl]glycine] or (R)βMeNphe [(R)‐N‐[(α‐methyl)benzyl]glycine] and l‐1‐naphthylalanine is incorporated into either position 7 or 11 of the parent compound. The synthesis and binding data of the Nnal6 ([N‐naphthylmethyl]glycine) analog of L‐363,301 is also reported. The incorporation of the Nnal residue into position 6 of L‐363,301 resulted in an analog with weaker binding affinities to all hsst receptors but enhanced selectivity towards the hsst2 receptor compared with the parent compound. The other compounds bind effectively to the hsst2 receptor but show some variations in the binding to the hsst3 and hsst5 receptors resulting in different ratios of binding affinities to the hsst5 and hsst2 or hsst3 and hsst2, respectively. The incorporation of the Nphe residue into position 6 and the Nal residue into position 7 of L‐363,301 led to a compound which binds potently to the hsst2 and has increased selectivity towards this receptor (weaker binding to hsst3 and hsst5 receptors) compared with the parent compound. The analogs with β‐methyl chiral substitutions in the aromatic peptoid side chain and Nal in position 7 or 11 bind effectively to the hsst2 and hsst5 receptors. They exhibit similar ratios of binding affinities to the hsst5 and hsst2 receptors as observed for L‐363,301. There are however minor differences in binding to the hsst3 receptor among these analogs. These studies allow us to investigate the influence of additional hydrophobic groups on the binding activity to the isolated human somatostatin receptors and the results are important for the design of other somatostatin analogs. Copyright © 1999 European Peptide Society and John Wiley &amp; Sons, Ltd.</description><subject>(R)-N-(α-methyl)benzylglycine</subject><subject>(R)βMeNphe</subject><subject>(R)βMeNphe, (R)‐N‐(α‐methyl)benzylglycine</subject><subject>(S)-N-(α-methyl)benzylglycine</subject><subject>(S)βMeNphe</subject><subject>(S)βMeNphe, (S)‐N‐(α‐methyl)benzylglycine</subject><subject>1-ethyl-3-(3′-dimethylaminopropyl)-carbodiimide</subject><subject>4-EM</subject><subject>4-ethylmorpholine</subject><subject>4‐EM, 4‐ethylmorpholine</subject><subject>binding activities</subject><subject>DCM</subject><subject>DCM, dichloromethane</subject><subject>dichloromethane</subject><subject>DIEA</subject><subject>DIEA, diisopropylethylamine</subject><subject>diisopropylethylamine</subject><subject>diphenylphosphoryl azide</subject><subject>DPPA</subject><subject>DPPA, diphenylphosphoryl azide</subject><subject>EDC</subject><subject>EDC, 1‐ethyl‐3‐(3′‐dimethylaminopropyl)‐carbodiimide</subject><subject>GH, growth hormone</subject><subject>growth hormone</subject><subject>hsst receptor</subject><subject>hsst receptor, recombinant human somatostatin receptor</subject><subject>hsst receptors</subject><subject>N-(naphthylmethyl)glycine</subject><subject>N-benzylglycine</subject><subject>Nnal</subject><subject>Nnal, N‐(naphthylmethyl)glycine</subject><subject>Nphe</subject><subject>Nphe, N‐benzylglycine</subject><subject>peptoids</subject><subject>recombinant human somatostatin receptor</subject><subject>somatostatin analogs</subject><subject>synthesis</subject><issn>1075-2617</issn><issn>1099-1387</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQQCNEJUrhP-SE2kMWf8RxskClEmC7VbWLFFCPI8d2uqbZOMSuaK78cpym2guIkz1jzZvxvCj6gNECI0Tenlbrcn2GUVEkmOb8FBdFgegZW9L3GNPl8mL9KflalZhn53SBFuX2HUk2z6LjQ8Xz6c5ZQjLMX0QvnfuBUHhj2XH0uxo7v9POuFh0Kq5Np0x3G_fW604a7WLbxHKUrd3pB9Hr3hulY2f3wlvnhTddKBOtvXWxtJ0XppuqO9Hv_G5sRStCrB_JYpjiu7GNJ4o1Kh5CV3Wv3avoqBGt06-fzpPo-5fP38rL5Hq7WpcX14mkOcoSLPI0yyTjSqGsZmlKZE6EVLrOiUopJrQpCGk0aaRkBKeaFSkhdYFkjuqaa3oSvZm5_WB_hr4e9sZJ3YYhtb13QDBmmPCCHgaQg3Vu0A30g9mHDwBGMBkBmIzAtF-Y9guzEWBAIRgBCEZgNhIyCMotENgE7s3M_WVaPf4F_T_zn8inTCAnM9k4rx8OZDHcQcYpZ3CzWcHHVcWrqxRDRv8Azpqx1Q</recordid><startdate>199903</startdate><enddate>199903</enddate><creator>Tran, Thuy-Anh</creator><creator>Mattern, Ralph-Heiko</creator><creator>Morgan, Barry A.</creator><creator>Taylor, John E.</creator><creator>Goodman, Murray</creator><general>John Wiley &amp; Sons, Ltd</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>199903</creationdate><title>Synthesis and binding potencies of cyclohexapeptide somatostatin analogs containing naphthylalanine and arylalkyl peptoid residues</title><author>Tran, Thuy-Anh ; Mattern, Ralph-Heiko ; Morgan, Barry A. ; Taylor, John E. ; Goodman, Murray</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3806-1a8466c57dd06b5442c82acdeb82d43123f922fe2fcc5214e59422b90c80bb7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>(R)-N-(α-methyl)benzylglycine</topic><topic>(R)βMeNphe</topic><topic>(R)βMeNphe, (R)‐N‐(α‐methyl)benzylglycine</topic><topic>(S)-N-(α-methyl)benzylglycine</topic><topic>(S)βMeNphe</topic><topic>(S)βMeNphe, (S)‐N‐(α‐methyl)benzylglycine</topic><topic>1-ethyl-3-(3′-dimethylaminopropyl)-carbodiimide</topic><topic>4-EM</topic><topic>4-ethylmorpholine</topic><topic>4‐EM, 4‐ethylmorpholine</topic><topic>binding activities</topic><topic>DCM</topic><topic>DCM, dichloromethane</topic><topic>dichloromethane</topic><topic>DIEA</topic><topic>DIEA, diisopropylethylamine</topic><topic>diisopropylethylamine</topic><topic>diphenylphosphoryl azide</topic><topic>DPPA</topic><topic>DPPA, diphenylphosphoryl azide</topic><topic>EDC</topic><topic>EDC, 1‐ethyl‐3‐(3′‐dimethylaminopropyl)‐carbodiimide</topic><topic>GH, growth hormone</topic><topic>growth hormone</topic><topic>hsst receptor</topic><topic>hsst receptor, recombinant human somatostatin receptor</topic><topic>hsst receptors</topic><topic>N-(naphthylmethyl)glycine</topic><topic>N-benzylglycine</topic><topic>Nnal</topic><topic>Nnal, N‐(naphthylmethyl)glycine</topic><topic>Nphe</topic><topic>Nphe, N‐benzylglycine</topic><topic>peptoids</topic><topic>recombinant human somatostatin receptor</topic><topic>somatostatin analogs</topic><topic>synthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tran, Thuy-Anh</creatorcontrib><creatorcontrib>Mattern, Ralph-Heiko</creatorcontrib><creatorcontrib>Morgan, Barry A.</creatorcontrib><creatorcontrib>Taylor, John E.</creatorcontrib><creatorcontrib>Goodman, Murray</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of peptide science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tran, Thuy-Anh</au><au>Mattern, Ralph-Heiko</au><au>Morgan, Barry A.</au><au>Taylor, John E.</au><au>Goodman, Murray</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and binding potencies of cyclohexapeptide somatostatin analogs containing naphthylalanine and arylalkyl peptoid residues</atitle><jtitle>Journal of peptide science</jtitle><addtitle>J. Peptide Sci</addtitle><date>1999-03</date><risdate>1999</risdate><volume>5</volume><issue>3</issue><spage>113</spage><epage>130</epage><pages>113-130</pages><issn>1075-2617</issn><eissn>1099-1387</eissn><abstract>We report the synthesis, binding affinities to the recombinant human somatostatin receptors, and structure‐activity relationship studies of compounds related to the cyclic hexapeptide, c‐[Pro6‐Phe7‐D‐Trp8‐Lys9‐Thr10‐Phe11], L‐363,301 (the numbering in the sequence refers to the position of the residues in native somatostatin). The Pro residue in this compound is replaced with the arylalkyl peptoid residues Nphe (N‐benzylglycine), (S)βMeNphe [(S)‐N‐[(α‐methyl)benzyl]glycine] or (R)βMeNphe [(R)‐N‐[(α‐methyl)benzyl]glycine] and l‐1‐naphthylalanine is incorporated into either position 7 or 11 of the parent compound. The synthesis and binding data of the Nnal6 ([N‐naphthylmethyl]glycine) analog of L‐363,301 is also reported. The incorporation of the Nnal residue into position 6 of L‐363,301 resulted in an analog with weaker binding affinities to all hsst receptors but enhanced selectivity towards the hsst2 receptor compared with the parent compound. The other compounds bind effectively to the hsst2 receptor but show some variations in the binding to the hsst3 and hsst5 receptors resulting in different ratios of binding affinities to the hsst5 and hsst2 or hsst3 and hsst2, respectively. The incorporation of the Nphe residue into position 6 and the Nal residue into position 7 of L‐363,301 led to a compound which binds potently to the hsst2 and has increased selectivity towards this receptor (weaker binding to hsst3 and hsst5 receptors) compared with the parent compound. The analogs with β‐methyl chiral substitutions in the aromatic peptoid side chain and Nal in position 7 or 11 bind effectively to the hsst2 and hsst5 receptors. They exhibit similar ratios of binding affinities to the hsst5 and hsst2 receptors as observed for L‐363,301. There are however minor differences in binding to the hsst3 receptor among these analogs. These studies allow us to investigate the influence of additional hydrophobic groups on the binding activity to the isolated human somatostatin receptors and the results are important for the design of other somatostatin analogs. Copyright © 1999 European Peptide Society and John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><doi>10.1002/(SICI)1099-1387(199903)5:3&lt;113::AID-PSC176&gt;3.0.CO;2-N</doi><tpages>18</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1075-2617
ispartof Journal of peptide science, 1999-03, Vol.5 (3), p.113-130
issn 1075-2617
1099-1387
language eng
recordid cdi_proquest_miscellaneous_21151279
source Wiley Journals
subjects (R)-N-(α-methyl)benzylglycine
(R)βMeNphe
(R)βMeNphe, (R)‐N‐(α‐methyl)benzylglycine
(S)-N-(α-methyl)benzylglycine
(S)βMeNphe
(S)βMeNphe, (S)‐N‐(α‐methyl)benzylglycine
1-ethyl-3-(3′-dimethylaminopropyl)-carbodiimide
4-EM
4-ethylmorpholine
4‐EM, 4‐ethylmorpholine
binding activities
DCM
DCM, dichloromethane
dichloromethane
DIEA
DIEA, diisopropylethylamine
diisopropylethylamine
diphenylphosphoryl azide
DPPA
DPPA, diphenylphosphoryl azide
EDC
EDC, 1‐ethyl‐3‐(3′‐dimethylaminopropyl)‐carbodiimide
GH, growth hormone
growth hormone
hsst receptor
hsst receptor, recombinant human somatostatin receptor
hsst receptors
N-(naphthylmethyl)glycine
N-benzylglycine
Nnal
Nnal, N‐(naphthylmethyl)glycine
Nphe
Nphe, N‐benzylglycine
peptoids
recombinant human somatostatin receptor
somatostatin analogs
synthesis
title Synthesis and binding potencies of cyclohexapeptide somatostatin analogs containing naphthylalanine and arylalkyl peptoid residues
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T22%3A28%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20binding%20potencies%20of%20cyclohexapeptide%20somatostatin%20analogs%20containing%20naphthylalanine%20and%20arylalkyl%20peptoid%20residues&rft.jtitle=Journal%20of%20peptide%20science&rft.au=Tran,%20Thuy-Anh&rft.date=1999-03&rft.volume=5&rft.issue=3&rft.spage=113&rft.epage=130&rft.pages=113-130&rft.issn=1075-2617&rft.eissn=1099-1387&rft_id=info:doi/10.1002/(SICI)1099-1387(199903)5:3%3C113::AID-PSC176%3E3.0.CO;2-N&rft_dat=%3Cproquest_cross%3E21151279%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21151279&rft_id=info:pmid/&rfr_iscdi=true